165 related articles for article (PubMed ID: 33906875)
1. Nivolumab with radiation therapy in a glioblastoma patient with Lynch syndrome.
Sherman WJ; Vitaz TW
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33906875
[TBL] [Abstract][Full Text] [Related]
2. Early Presentation of Homozygous Mismatch Repair Deficient Glioblastoma in Teen With Lynch Syndrome: Implications for Treatment and Surveillance.
Thomsen W; Maese L; Vagher J; Moore K; Cheshier SH; Hofmann JW; Bruggers C
JCO Precis Oncol; 2021 Nov; 5():670-675. PubMed ID: 34994609
[No Abstract] [Full Text] [Related]
3. Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab.
Kawashima Y; Nishikawa S; Ninomiya H; Yoshida R; Takano N; Oguri T; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Ishikawa Y; Nishio M
Intern Med; 2019; 58(10):1479-1484. PubMed ID: 31092773
[TBL] [Abstract][Full Text] [Related]
4. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
[TBL] [Abstract][Full Text] [Related]
5. High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.
Anghileri E; Di Ianni N; Paterra R; Langella T; Zhao J; Eoli M; Patanè M; Pollo B; Cuccarini V; Iavarone A; Rabadan R; Finocchiaro G; Pellegatta S
Cancer Immunol Immunother; 2021 Mar; 70(3):831-842. PubMed ID: 33140187
[TBL] [Abstract][Full Text] [Related]
6. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
[TBL] [Abstract][Full Text] [Related]
7. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
[TBL] [Abstract][Full Text] [Related]
8. Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer.
Winer A; Ghatalia P; Bubes N; Anari F; Varshavsky A; Kasireddy V; Liu Y; El-Deiry WS
Oncologist; 2019 Nov; 24(11):1416-1419. PubMed ID: 31444293
[TBL] [Abstract][Full Text] [Related]
9. Lynch Syndrome-Associated Glioblastoma Treated With Concomitant Chemoradiotherapy and Immune Checkpoint Inhibitors: Case Report and Review of Literature.
Nakase K; Matsuda R; Sasaki S; Nakagawa I
Brain Tumor Res Treat; 2024 Jan; 12(1):70-74. PubMed ID: 38317491
[TBL] [Abstract][Full Text] [Related]
10. [A Case of Diagnosed Lynch Syndrome in a Patient with Ureteral Cancer].
Kobayashi G; Takayanagi A; Shindo T; Hashimoto K; Kobayashi K; Fukuta F; Tanaka T; Masumori N
Hinyokika Kiyo; 2021 Jun; 67(6):229-232. PubMed ID: 34265897
[TBL] [Abstract][Full Text] [Related]
11. Lynch syndrome in colorectal cancer patients.
Giráldez MD; Castellví-Bel S; Balaguer F; Gonzalo V; Ocaña T; Castells A
Expert Rev Anticancer Ther; 2008 Apr; 8(4):573-83. PubMed ID: 18402524
[TBL] [Abstract][Full Text] [Related]
12. Lynch Syndrome/Hereditary Non-polyposis Colorectal Cancer (HNPCC).
Stoffel EM
Minerva Gastroenterol Dietol; 2010 Mar; 56(1):45-53. PubMed ID: 20190724
[TBL] [Abstract][Full Text] [Related]
13. Lynch Syndrome: A Primer for Urologists and Panel Recommendations.
Mork M; Hubosky SG; Rouprêt M; Margulis V; Raman J; Lotan Y; O'Brien T; You N; Shariat SF; Matin SF
J Urol; 2015 Jul; 194(1):21-9. PubMed ID: 25711197
[TBL] [Abstract][Full Text] [Related]
14. A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Zhu VW; Hinduja S; Knezevich SR; Silveira WR; DeLozier CD
Clin Neurol Neurosurg; 2017 Jul; 158():46-48. PubMed ID: 28460341
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Undifferentiated Carcinoma of the Sella in a Patient with Lynch Syndrome.
Voisin MR; Almeida JP; Perez-Ordonez B; Zadeh G
World Neurosurg; 2019 Dec; 132():219-222. PubMed ID: 31491579
[TBL] [Abstract][Full Text] [Related]
16. [Lynch syndrome: What is new?].
Pellat A; Netter J; Perkins G; Cohen R; Coulet F; Parc Y; Svrcek M; Duval A; André T
Bull Cancer; 2019; 106(7-8):647-655. PubMed ID: 30527816
[TBL] [Abstract][Full Text] [Related]
17. Mismatch repair from Lynch syndrome to immunotherapy: A brief primer for cytopathologists.
Kerr SE
Cancer Cytopathol; 2020 Aug; 128(8):515-517. PubMed ID: 32196978
[No Abstract] [Full Text] [Related]
18. Lynch Syndrome: From Screening to Diagnosis to Treatment in the Era of Modern Molecular Oncology.
Cohen SA; Pritchard CC; Jarvik GP
Annu Rev Genomics Hum Genet; 2019 Aug; 20():293-307. PubMed ID: 30848956
[TBL] [Abstract][Full Text] [Related]
19. Mismatch repair gone awry: Management of Lynch syndrome.
Zhang T; Boswell EL; McCall SJ; Hsu DS
Crit Rev Oncol Hematol; 2015 Mar; 93(3):170-9. PubMed ID: 25459670
[TBL] [Abstract][Full Text] [Related]
20. Hereditary prostate cancer as a feature of Lynch syndrome.
Bauer CM; Ray AM; Halstead-Nussloch BA; Dekker RG; Raymond VM; Gruber SB; Cooney KA
Fam Cancer; 2011 Mar; 10(1):37-42. PubMed ID: 20872076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
